-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Combination chemotherapy based on platinum drugs is the standard treatment for chemotherapy-qualified patients with metastatic urothelial carcinoma (mUC).
immunity
This study aims to evaluate the effectiveness and safety of ICI alone or in combination with other drugs as a first-line treatment for mUC patients who meet the requirements of chemotherapy .
To evaluate the effectiveness and safety of ICI alone or in combination with other drugs as a first-line treatment plan for mUC patients who meet chemotherapy requirements
The researchers searched multiple data articles published before November 2020, screened and compared the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and complete response rate of mUC patients who meet the requirements of chemotherapy.
Relative OS, PFS, ORR of different treatment groups
Relative OS, PFS, ORR of different treatment groupsA total of 3 studies that met the inclusion criteria were screened.
Compared with chemotherapy alone, ICI combination therapy is associated with better OS and PFS, higher CRR and longer DOR
OS and PFS in patients with high and low expression of PD-L1
OS and PFS in patients with high and low expression of PD-L1Compared with chemotherapy alone, the ICI-chemotherapy combination can also significantly increase OS and PFS, increase ORR and CRR, and prolong DOR .
The ICI-chemotherapy combination can also significantly increase OS and PFS, increase ORR and CRR, and prolong DOR
However, ICI monotherapy cannot improve the tumor prognosis of patients compared with chemotherapy alone, but the safety prognosis is relatively good .
ICI monotherapy does not improve the tumor prognosis of patients compared with chemotherapy alone, but the safety prognosis is relatively good
In summary, the analysis suggests that mUC patients who are eligible for chemotherapy are better than standard chemotherapy when using ICI combination therapy as a first-line treatment plan .
Patients with mUC who are eligible for chemotherapy use ICI combination therapy as the first-line treatment plan.
Original source:
Mori Keiichiro, Pradere Benjamin, Moschini Marco et al.
org/10.
1016/j.
ejca.
2021.
03.
049">First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis
in this message
